Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.345
Abstract: 345Background: GVAX is composed of irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF and induce broad tumor antigen responses. Low-dose cyclophosphamide (CY) is administered with GVAX to inhibit regulatory T cells. CRS-207 is live,…
read more here.
Keywords:
chemotherapy;
results phase;
crs 207;
study ... See more keywords